European Pharmaceutical Manufacturer covers the pharma and biopharma supply chain from formulation through distribution, providing audiences with the latest news, opinions, and innovations from an industry full of technological progress.
There’s a significant opportunity for biosimilar manufacturers to gain market share from reference biologics whose patents are expiring between late 2018 and 2023 in both Europe and the US. However, Owen Mumford Pharmaceutical Services notes that even with clinical support for biosimilars, some key issues still need to be addressed. This article takes a closer look at those concerns and what industry insiders need to keep in mind.
You’ll find the article on page 27 via the link below.